Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 1.00 |
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | RXRB | P28702 | 10/20 | 0.66 |
| ▸ | RXRG | P48443 | 6/20 | 0.61 |
| ▸ | RARB | P10826 | 5/20 | 0.61 |
| ▸ | RARG | P13631 | 5/20 | 0.61 |
| ▸ | RARA | P10276 | 3/20 | 0.58 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894384 | 0.95 | RXRA (1.00) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL31061276 | 0.90 | CYP26B1 (1.00) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL29391180 | 0.90 | CYP26B1 (1.00) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL3454051 | 0.90 | CYP26B1 (1.00) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL8708782 | 0.85 | RXRA (0.74) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL30012842 | 0.84 | RXRA (1.00) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL3453249 | 0.84 | RXRA (1.00) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL7521288 | 0.84 | RXRA (0.74) | RXRACYP26B1CYP26A1RXRBRXRG | |
| SCHEMBL8706133 | 0.81 | RXRA (0.76) | RXRACYP26B1CYP26A1CYP3A4RXRB | |
| SCHEMBL17911582 | 0.81 | CYP26B1 (1.00) | RXRACYP26B1CYP26A1CYP3A4RXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
| US-20110300129-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010075037-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2010-07-01 | — | — | WO | disclosed |
| US-5837725-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | CYP2B6, CYP26A1, CYP2A6 | RXRA 15/4885CYP26B1 4/4885CYP26A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.